LOS ANGELES --(BUSINESS WIRE)--Sep. 17, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA ® -Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel for the treatment of
LOS ANGELES --(BUSINESS WIRE)--Sep. 9, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 3:30 p.m. ET on Monday, September 14, at the H.C.
LOS ANGELES --(BUSINESS WIRE)--Sep. 3, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 33,550 shares of
Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES --(BUSINESS WIRE)--Aug. 6, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2026.
LOS ANGELES --(BUSINESS WIRE)--Aug. 5, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 35,375 shares of Puma
LOS ANGELES --(BUSINESS WIRE)--Jul. 23, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 6, 2026, following the release of its second quarter 2026 financial results.
LOS ANGELES --(BUSINESS WIRE)--Jul. 2, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma
LOS ANGELES --(BUSINESS WIRE)--Jun. 3, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 7,000 shares of Puma
Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES --(BUSINESS WIRE)--May 7, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026.
LOS ANGELES --(BUSINESS WIRE)--May 6, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 59,750 shares of Puma
